Publication details
Rabeprazol - blokátor protonové pumpy 2. generace
| Title in English | Rabeprazole: A second-generation proton pump inhibitor |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | Gastroesophageal reflux; Proton pump inhibitor; Rabeprazole; Ulcer disease |
| Description | The introduction in the 1980s of proton pump inhibitors in the treatment of diseases, collectively referred to as gastric acid-related diseases, became a major breakthrough in terms of treatment efficacy for these conditions. Currently, proton pump inhibitors are divided into first-generation drugs (omeprazole, lansoprazole, pantoprazole) and second-generation drugs that include esomeprazole, the optical isomer of omeprazole, and rabeprazole. Rabeprazole is the most recent of the proton pump inhibitors available at the Czech pharmaceutical market. As other proton pump inhibitors, rabeprazole is safe and its advantage, in comparison with first-generation drugs, is a rapid onset of suppression of gastric acid production and, thus, a rapid esions, primarily managed endoscopically, in which rabeprazole administered orally was as effective as omeprazole given intravenously. Due to the differences of rabeprazole metabolism by cytochrome P450 compared to other proton pump inhibitors, there are fewer drug interactions with rabeprazole. Rabeprazole is a drug with a high therapeutic efficacy for diseases related to the presence of gastric hydrochloric acid. |